Is Cellebrite DI Ltd. (CLBT) A Good Stock To Buy Now?

Is CLBT a good stock to buy? We came across a bullish thesis on Cellebrite DI Ltd. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on CLBT. Cellebrite DI Ltd.’s share was trading at $13.38 as of April 20th. CLBT’s trailing and forward P/E were 43.16 and 35.71 respectively as reported by Yahoo Finance.

Copyright: welcomia / 123RF Stock Photo

Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. CLBT has established itself as the leading provider of digital forensics and investigative solutions, underpinned by a unique three-layer moat of proprietary device unlock technology, two decades of courtroom accreditation, and fully integrated workflow platforms. Its mobile device extraction tools, attached to 45% of the installed base, require constant R&D to keep pace with Apple and Google security updates, creating a living technical moat that competitors cannot replicate at scale.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Legal and regulatory accreditations further lock in institutional customers, as evidence collected with Cellebrite tools is admissible in courts across over 100 countries, creating switching costs that span years. The company’s integrated Case-to-Closure platform — combining device extraction, AI analytics, evidence management, and open-source intelligence — ensures that switching to competitors is operationally prohibitive, driving subscription-based revenue with net retention above 120%.

The 2025 Corellium acquisition expands Cellebrite’s capabilities into ARM-based devices, IoT, automotive, and smart infrastructure, while the SCG Canada acquisition positions the company in drone forensics, broadening its total addressable market. Structural tailwinds from digitization, rising mobile evidence, and expanding law enforcement and enterprise adoption underpin sustained growth, with ARR reaching $481M in 2025, 85% subscription-based, 34% FCF margins, and a cash-rich balance sheet of $484M.

Near-term catalysts include 2026 FedRAMP cloud authorization for US federal agencies and Guardian Investigate AI analytics rollout, which could accelerate ARR growth and deepen platform lock-in. Risks include federal spending volatility, device security escalations, human rights regulatory scrutiny, and Sun Corporation’s ~40% ownership overhang.

At $1.6B market cap and 3.4x revenue, CLBT offers 2.5–7x potential upside over 4–5 years through ARR compounding, platform expansion, and multiple re-rating, while retaining resilience from recurring revenue, geographic diversification, and mission-critical status in law enforcement workflows.

Previously, we covered a bullish thesis on DLocal Limited (DLO) by Oliver | MMMT Wealth in March 2025, which highlighted its long-term growth potential in emerging markets, unique positioning in cross-border payments, improving take rates, and stabilizing total payment volume. DLO’s stock price has appreciated by 38.91% since our coverage. Danny Green shares a similar view but emphasizes Cellebrite DI Ltd.’s (CLBT) three-layer moat, integrated workflow platform, and subscription-based revenue growth as key drivers.

Cellebrite DI Ltd. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held CLBT at the end of the fourth quarter which was 31 in the previous quarter. While we acknowledge the risk and potential of CLBT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CLBT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

Disclosure: None.